We carefully read the article by Cacciapaglia et al. published in the European Journal of Internal Medicine [1]. This study reveals the suboptimal adherence to lipid-lowering therapy prescriptions in rheumatoid arthritis (RA) patients, despite their high cardiovascular risk. Although the authors mentioned some limitations, we believe several points deserve further discussion to enrich the findings and inform future intervention strategies.
